This site is intended for healthcare professionals

FDA accepts for review sNDA for Otezla to treat mild-to-moderate plaque psoriasis patients who are candidates for phototherapy or systemic therapy. Amgen

Read time: 1 mins
Last updated:28th Jun 2021
Published:6th May 2021
Amgen has announced that the FDA has accepted for review the supplemental New Drug Application (sNDA) for Otezla (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy.
Condition: Psoriasis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest